FutureTox IV

Predictive Toxicology for Healthy Children

November 14–16, 2018 | Crystal City, VA

about FutureTox IV


FutureTox IV Progress to Maturity: Predictive Developmental and Reproductive Toxicology for Healthy Children is focused on bringing together basic, clinical, and regulatory scientists to bridge the translation from historical approaches to Tox21 implementation relative to risk assessment and regulatory decision-making for matters pertaining to developmental health, lifestage progression, and the human reproductive cycle. The meeting also will look at implementing the 21st-century vision and regulatory considerations relevant to commercial chemicals in the environment and medical products for guidance based on new results.

The FutureTox series focuses on building the road for 21st-century toxicology and risk assessment practices, utilizing in vitro data and in silico models for predictive toxicology, and taking the high-throughput risk assessment paradigm forward to address challenges in implementing the emerging big-data toolbox for risk assessment and regulatory decision-making.

Background and Vision for the Conference

  Why Children’s Health?

The prevalence of adverse children’s health outcomes in the US demonstrates a growing need for research to understand the impact of environmental factors on human development and for actionable solutions to ensure well-being across lifestages and to recognize that adverse consequences may not manifest until later in life or in subsequent generations.

Adverse developmental outcomes such as preterm labor, low birth weight, birth defects, childhood asthma, neurodevelopmental impairment, pubertal timing, cardiovascular disease, metabolic syndrome, subfertility, and pediatric cancers are some examples of important considerations for healthy children.

  What FutureTox IV Will Address

Current translational opportunities and challenges for in vitro data and in silico models in developmental effects assessment, such as:

  • Integration of high-throughput data from biomolecular screening efforts with current and emerging biological understanding;
  • Engineering human cell-based organotypic culture models that effectively recapitulate key events in developmental-reproductive processes;
  • Constructing adverse outcome pathways (AOPs) relevant to regulatory decision-making on potential developmental hazards; and
  • Exposure-based metrics to address risk assessment for children’s health and well-being.

  Regulatory Implications

With the 2016 Frank R. Lautenberg Chemical Safety for the 21st Century Act highlighting children and pregnant women as sensitive lifestages and populations, there is renewed impetus for implementing new assays and technologies to address the safety of the >80,000 compounds in commerce. This requires confidence in the high-throughput testing paradigm, as well as effective communication of the emerging science and technology to stakeholders.

Recent investments by the Defense Advanced Research Projects Agency (DARPA), US Food and Drug Administration (US FDA), National Institutes of Health (NIH), US Environmental Protection Agency (US EPA), and other federal agencies in the US and Europe are investing in the development and implementation of alternative testing strategies such as human organ-on-chip and microphysiological system constructs to support human disease models; however, these platforms could be translated in support of regulatory decision-making for toxicity testing.

Preliminary Agenda


More information regarding abstracts/posters will be available in late Spring 2018.


The Westin
Crystal City

Arlington, Virginia

more info


Coming April 30, 2018

Organizing Committee

Thomas B. Knudsen, PhD

US Environmental Protection Agency, National Center for Computational Toxicology, Research Triangle Park, NC

Suzanne Fitzpatrick, PhD

US Food and Drug Administration, Center for Food Safety and Applied Nutrition, College Park, MD

K. Nadira De Abrew, PhD

Procter & Gamble Company, Cincinnati, OH

Anne Chappelle, PhD

SOT Council Contact
International Isocyanate Institute, Chadds Ford, PA

Alison Elder, PhD

Contemporary Concepts in Toxicology (CCT) Conferences Committee Liaison
University of Rochester, Rochester, NY

Sue Euling, PhD

US Environmental Protection Agency, Office of Children’s Health Protection, Washington, DC

Elaine Faustman, PhD

University of Washington, Seattle, WA

Jill Franzosa

US Environmental Protection Agency, Office of Research and Development, Chemical Safety for Sustainability, Research Triangle Park, NC

Laurie Haws, PhD

ToxStrategies, Inc., Austin, TX

Nicole Kleinstreuer, PhD

National Toxicology Program, Durham, NC

Germaine Buck Louis, PhD

College of Health and Human Services, George Mason University, Fairfax, VA

Donna L. Mendrick, PhD

US Food and Drug Administration, National Center for Toxicological Research, Silver Spring, MD

Ruthann Rudel, MS

Silent Spring Institute, Newton, MS

Thad Schug, PhD

National Institute of Environmental Health Sciences, Research Triangle Park, NC

Robert Tanguay, PhD

Oregon State University, Corvallis, OR

Barbara Wetmore, PhD

US Environmental Protection Agency, National Exposure Research Laboratory, Research Triangle Park, NC

Kimberly White, PhD

American Chemistry Council, Washington, DC

Executive Committee

Linda S. Birnbaum, PhD

National Institute of Environmental Health Sciences, National Toxicology Program, Research Triangle Park, NC

George P. Daston, PhD

Procter & Gamble Company, Cincinnati, OH

Dana C. Dolinoy, PhD

University of Michigan, School of Public Health, Ann Arbor, MI

Kristi Pullen Fedinick, PhD,

Natural Resources Defense Council, Washington, DC


Become a sponsor

Interested in becoming a sponsor? Learn about opportunities and benefits.

request info


11190 Sunrise Valley Drive, Suite 300, Reston, VA 20191-4375